Skip to main content

Table 2 The Los Angeles classification and Lanza scores at baseline and after treatment

From: Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study

  Baseline Post-treatment p value1
Irsogladine group    
Los Angeles classification Grade O (16/16) Grade O (16/16)  
Lanza scores (stomach) (mean ± SD) 0.5 ± 1.1 0.9 ± 1.0 NS
Lanza scores (duodenum) (mean ± SD) 0.0 ± 0.0 0.4 ± 0.9 NS
Omeprazole group    NS
Los Angeles classification Grade O (16/16) Grade O (16/16)  
Lanza scores (stomach) (mean ± SD) 0.6 ± 0.9 1.5 ± 1.1 NS
Lanza scores (duodenum) (mean ± SD) 0.0 ± 0.0 0.4 ± 0.8 0.0049
  1. 1P-values are baseline versus post-treatment within groups.